These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8107264)

  • 1. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
    Kaplan AH; Michael SF; Wehbie RS; Knigge MF; Paul DA; Everitt L; Kempf DJ; Norbeck DW; Erickson JW; Swanstrom R
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5597-601. PubMed ID: 8202533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
    Borman AM; Paulous S; Clavel F
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():419-26. PubMed ID: 8601776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
    Markowitz M; Mo H; Kempf DJ; Norbeck DW; Bhat TN; Erickson JW; Ho DD
    J Virol; 1995 Feb; 69(2):701-6. PubMed ID: 7815532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
    Baldwin ET; Bhat TN; Liu B; Pattabiraman N; Erickson JW
    Nat Struct Biol; 1995 Mar; 2(3):244-9. PubMed ID: 7773792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.
    Lech WJ; Wang G; Yang YL; Chee Y; Dorman K; McCrae D; Lazzeroni LC; Erickson JW; Sinsheimer JS; Kaplan AH
    J Virol; 1996 Mar; 70(3):2038-43. PubMed ID: 8627733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
    Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
    Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
    Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML; Potts KE; Tucker SP; Blystone L; Stiebel TR; Stallings WC; McDonald JJ; Pillay D; Richman DD; Bryant ML
    Antimicrob Agents Chemother; 1997 Mar; 41(3):515-22. PubMed ID: 9055985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
    el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
    J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
    Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
    J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
    Doyon L; Croteau G; Thibeault D; Poulin F; Pilote L; Lamarre D
    J Virol; 1996 Jun; 70(6):3763-9. PubMed ID: 8648711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus. Protease uninhibited.
    Richman DD
    Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
    [No Abstract]   [Full Text] [Related]  

  • 19. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.
    King RW; Winslow DL; Garber S; Scarnati HT; Bachelor L; Stack S; Otto MJ
    Antiviral Res; 1995 Sep; 28(1):13-24. PubMed ID: 8585757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.